Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Bispecific antibodies are effective for relapsed/refractory B-cell lymphoma patients even after CAR-T therapy.
Methods: Peripheral blood CAR-T kinetics and functional analysis in vivo were carried out pre- and post-epcoritamab infusion in B-cell lymphoma patients relapsing after CAR-T therapy.
Results: CAR copy numbers spiked at relapse and rose again following epcoritamab administration. Expression levels of CAR-T exhaustion markers did not increase, whereas perforin and granzyme B expression increased after epcoritamab induction.
Conclusion: Early epcoritamab administration without cytotoxic agents at relapse after CAR-T therapy revives CAR-T cell numbers and cytotoxicity, which may potentially lead to favorable clinical outcomes.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12172560 | PMC |
| http://dx.doi.org/10.1002/jha2.70079 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Bispecific Antibodies-A New Hope for Patients with Diffuse Large B-Cell Lymphoma.
J Clin Med
August 2025
Faculty of Medicine, "Lucian Blaga" University of Sibiu, 550024 Sibiu, Romania.
T-cell-engaging antibodies are a promising new type of treatment for patients with refractory or relapsed (R/R) diffuse large B-cell lymphoma, which has changed the prognosis and evolution of these patients in clinical trials. Bispecific antibodies (BsAbs) bind to two different targets (B and T lymphocytes) at the same time and in this way mimic the action of CAR (chimeric antigen receptor) T-cells. They are the T-cell-engaging antibodies most used in practice and are a solution for patients who do not respond to second- or later-line therapies, including chemoimmunotherapy, followed by salvage chemotherapy and hematopoietic stem cell transplantation.
View Article and Find Full Text PDFBackground: Bispecific antibodies are effective for relapsed/refractory B-cell lymphoma patients even after CAR-T therapy.
Methods: Peripheral blood CAR-T kinetics and functional analysis in vivo were carried out pre- and post-epcoritamab infusion in B-cell lymphoma patients relapsing after CAR-T therapy.
Results: CAR copy numbers spiked at relapse and rose again following epcoritamab administration.
Heavily Pretreated Refractory Diffuse Large B-Cell Lymphoma Successfully Treated with Epcoritamab: Case Report.
Case Rep Oncol
March 2025
Alaska Oncology and Hematology, Alaska Regional Hospital, Anchorage, AK, USA.
Introduction: Relapsed or refractory diffuse large B-cell lymphoma (DLBCL) poses considerable treatment challenges, with disheartening odds of long-term survival. Numerous strategies exist, including non-cross-resistant combination chemoimmunotherapy regimens, autologous stem cell transplantation, and chimeric antigen receptor (CAR) T-cell therapy, but some patients are not appropriate candidates or cannot sustain response to treatment. Epcoritamab, a bispecific CD20-directed CD3 T-cell engager, has been given accelerated approval by the US Food and Drug Administration for relapsed or refractory DLBCL.
View Article and Find Full Text PDFQSP modeling of loncastuximab tesirine with T-cell-dependent bispecific antibodies guides dose-regimen strategy.
NPJ Syst Biol Appl
June 2025
Metrum Research Group, 68 Harrison Ave, Boston, MA, USA.
Antibody-drug conjugates (ADCs) and T-cell-dependent bispecific antibodies (TDBs) show single-agent efficacy in relapsed/refractory (R/R) lymphomas. While coadministering therapeutics with orthogonal mechanisms of action may safely enhance efficacy, testing every potential combination regimen is infeasible in the clinic. An integrated quantitative systems pharmacology model of a CD19-targeted ADC and CD3/CD20-targeted TDBs was developed to predict combination regimen efficacy in R/R diffuse large B-cell lymphoma (DLBCL).
View Article and Find Full Text PDFCD20×CD3 Bispecific Antibodies in B-NHL: A Review of Translational Science, Pharmacokinetics, Pharmacodynamics, and Dose Strategy in Clinical Research.
Clin Transl Sci
June 2025
Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.
Despite advancements in treatment for B-cell non-Hodgkin lymphoma (B-NHL) in recent decades, many patients still relapse or are refractory to treatment, which represents a high unmet medical need. Novel CD20 × CD3 T-cell-engaging bispecific antibodies (bsAbs) have created a new paradigm for the treatment of B-NHL. Pivotal studies of four CD20 × CD3 bsAbs, mosunetuzumab, glofitamab, epcoritamab, and odronextamab, as monotherapy, have demonstrated robust responses with generally manageable safety profiles in patients with relapsed or refractory follicular lymphoma and diffuse large B-cell lymphoma after ≥ 2 lines of systemic therapy.
View Article and Find Full Text PDF